How will we use the new antiviral agents for hepatitis B?

[1]  S. Nair,et al.  Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: Is sustained clearance of HBV DNA dependent on levels of pretreatment viremia? , 2001, Hepatology.

[2]  P. Marcellin,et al.  GS-98-437 a double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for the treatment of patients with HBeAg+ chronic hepatitis B infection: 48 week results. , 2001 .

[3]  M. Sherman,et al.  Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection , 2001, Hepatology.

[4]  D. Häussinger,et al.  Protein kinase C–dependent distribution of the multidrug resistance protein 2 from the canalicular to the basolateral membrane in human HepG2 cells , 2001, Hepatology.

[5]  N. Leung,et al.  Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy , 2001, Hepatology.

[6]  A. Lok,et al.  Management of hepatitis B: 2000--summary of a workshop. , 2001, Gastroenterology.

[7]  H. Janssen,et al.  Durability of hbeag seroconversion in chronic hepatitis B patients after lamivudine A-interferon or lamivudine A- interferon combination therapy , 2001 .

[8]  G. Ogg,et al.  Lamivudine treatment can overcome cytotoxic T‐cell hyporesponsiveness in chronic hepatitis B: New perspectives for immune therapy , 2001, Hepatology.

[9]  R. Perrillo.  Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. , 2001, Gastroenterology.

[10]  R. Schinazi,et al.  The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. , 2001, The Journal of clinical investigation.

[11]  C. K. Chu,et al.  Antiviral activity of clevudine [L‐FMAU, (1‐(2‐fluoro‐5‐methyl‐β, L‐arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax) , 2001, Hepatology.

[12]  M. Myers,et al.  Safe and potent suppression of hepatitis B virus (HBV) with L-deoxythymidine (LDT): Results of a dose-escalation trial , 2001 .

[13]  J. Reichen,et al.  Peginterferon alfa-2a in patients with chronic hepatitis C. , 2000, The New England journal of medicine.

[14]  D. Pillay,et al.  Additive antiviral effects of lamivudine and alpha-interferon in chronic hepatitis B infection. , 2000, Antiviral therapy.

[15]  H. Lee,et al.  Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea , 2000, Hepatology.

[16]  C. Chu,et al.  Prednisolone Priming Enhances Th1 Response and Efficacy of Subsequent Lamivudine Therapy in Patients With Chronic Hepatitis B , 2000, Hepatology.

[17]  R. D. de Man,et al.  Acute Exacerbation of Chronic Hepatitis B Virus Infection After Withdrawal of Lamivudine Therapy , 2000, Hepatology.

[18]  P. Marcellin,et al.  A randomized, placebo‐controlled study to evaluate the efficacy of 12‐month famciclovir treatment in patients with chronic hepatitis B e antigen–positive hepatitis B , 2000, Hepatology.

[19]  S. Locarnini,et al.  Combination chemotherapy for hepatitis B virus: The final solution? , 2000, Hepatology.

[20]  C. Gibbs,et al.  Combination therapy with lamivudine and famciclovir for chronic hepatitis B–infected Chinese patients: A viral dynamics study , 2000, Hepatology.

[21]  E. Schiff,et al.  Adefovir dipivoxil for the treatment of lamivudine‐resistant hepatitis B mutants , 2000, Hepatology.

[22]  H. Will,et al.  Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir In vitro do not lead to reduction of the closed circular DNA , 2000, Hepatology.

[23]  J. Jenkins,et al.  A study of the pharmacokinetic interaction between lamivudine and alpha interferon , 2000, European Journal of Clinical Pharmacology.

[24]  T. Berg,et al.  Antiviral combination therapy for lamivudine-resistant hepatitis B reinfection after liver transplantation , 2000 .

[25]  C. Hunt,et al.  Clinical relevance of hepatitis B viral mutations , 2000, Hepatology.

[26]  A. Dhillon,et al.  Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial , 2000, Gut.

[27]  S. Locarnini,et al.  Antiviral chemotherapy for the treatment of hepatitis B virus infections. , 2000, Gastroenterology.

[28]  D. Pillay,et al.  Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient , 2000, Gut.

[29]  R. Schinazi,et al.  Enhanced Antiviral Benefit of Combination Therapy with Lamivudine and Alpha Interferon against WHV Replication in Chronic Carrier Woodchucks , 1999, Antiviral therapy.

[30]  C. Gibbs,et al.  Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin. , 1999, Transplantation.

[31]  E. Schiff,et al.  Lamivudine as initial treatment for chronic hepatitis B in the United States. , 1999, The New England journal of medicine.

[32]  Y. Liaw,et al.  Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B , 1999, Hepatology.

[33]  C. Chu,et al.  Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy , 1999, Hepatology.

[34]  S. Hadziyannis,et al.  Oral ganciclovir treatment in chronic hepatitis B virus infection: a pilot study. , 1999, Journal of hepatology.

[35]  M. Manns,et al.  Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under hbig immunoglobulin after liver transplantation , 1999, Hepatology.

[36]  W. Hop,et al.  Interferon alfa for chronic hepatitis B infection: Increased efficacy of prolonged treatment , 1999, Hepatology.

[37]  C. Gibbs,et al.  Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy , 1999, Hepatology.

[38]  E. Schiff,et al.  Multicenter study of lamivudine therapy for hepatitis B after liver transplantation , 1999, Hepatology.

[39]  C. Gibbs,et al.  Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro , 1998, Hepatology.

[40]  J. Hoofnagle,et al.  Combination Therapy with Famciclovir and Interferon-α for the Treatment of Chronic Hepatitis B , 1998 .

[41]  C. Hunt,et al.  Clinical significance of YMDD mutant hepatitis B virus (HBV) in a large cohort of lamivudine-treated hepatitis B patients. , 1998 .

[42]  N. Leung,et al.  A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. , 1998, The New England journal of medicine.

[43]  J. Wands,et al.  Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective , 1998, Hepatology.

[44]  S. Locarnini,et al.  Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro , 1997, Hepatology.

[45]  R. Colonno,et al.  Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus , 1997, Antimicrobial agents and chemotherapy.

[46]  E. Keeffe,et al.  Ganciclovir treatment of hepatitis B virus infection in liver transplant recipients , 1996, Hepatology.

[47]  H. Conjeevaram,et al.  Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. , 1995, The New England journal of medicine.

[48]  E. Schiff,et al.  Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. , 1995, Gastroenterology.

[49]  T. Poynard,et al.  Prednisone‐interferon combination in the treatment of chronic hepatitis B: Direct and indirect metanalysis , 1994, Hepatology.

[50]  D. Tyrrell.  Phase II trial of lamivudine for chronic hepatitis B , 1993 .

[51]  A. Detsky,et al.  Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B , 1993, Annals of Internal Medicine.

[52]  E. Schiff,et al.  A Randomized, Controlled Trial of Interferon Alfa-2b Alone and after Prednisone Withdrawal for the Treatment of Chronic Hepatitis B , 1990 .

[53]  J. Hoofnagle,et al.  Randomized, controlled trial of recombinant human α-interferon in patients with chronic hepatitis B , 1988 .

[54]  R. Perrillo,et al.  Comparative efficacy of adenine arabinoside 5' monophosphate and prednisone withdrawal followed by adenine arabinoside 5' monophosphate in the treatment of chronic active hepatitis type B. , 1985, Gastroenterology.

[55]  J. Hoofnagle,et al.  Randomized controlled trial of adenine arabinoside monophosphate for chronic type B hepatitis. , 1984, Gastroenterology.

[56]  T. Merigan,et al.  Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. , 1976, The New England journal of medicine.